Ghost Tree Capital’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Ghost Tree Capital’s Portfolio RARX Stock Details RARX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-300,000	Closed	-$9.02M	–	54
2019 Q2	$9.02M	Hold	300,000	–	–	1.87%	15
2019 Q1	$6.72M	Buy	+300,000	New	+$6.45M	1.76%	23
2017 Q4	–	Sell	-235,000	Closed	-$3.43M	–	83
2017 Q3	$3.43M	Buy	235,000 +150,000	+176%	+$2.27M	0.73%	48
2017 Q2	$1.59M	Sell	85,000 -215,000	-72%	-$4.85M	0.33%	63
2017 Q1	$6.39M	Buy	300,000 +225,000	+300%	+$4.3M	1.19%	36
2016 Q4	$1.14M	Buy	+75,000	New	+$1.02M	0.27%	60

Other funds holding RARX

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Ghost Tree Capital's RARX Position: Q3 2019 in Review

Ghost Tree Capital sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q3 2019, closing a stake of 300,000 shares — an estimated $9.02M sold.

Ghost Tree Capital first reported a position in RARX in Q4 2016 and held it in 6 quarters. The position peaked at $9.02M in Q2 2019. 119 funds tracked by Wall St. Rank hold RARX as of Q3 2019.

Ghost Tree Capital reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
Ghost Tree Capital sold 300,000 Ra Pharmaceuticals, Inc. Common Stock shares in Q3 2019, an estimated $9.02M.
Ghost Tree Capital first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q4 2016 and held it in 6 quarters.
Ghost Tree Capital's Ra Pharmaceuticals, Inc. Common Stock position peaked at $9.02M in Q2 2019.
119 funds tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q3 2019.

Based on Ghost Tree Capital's 13F filing for Q3 2019, filed 14 Nov 2019.